<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name></publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2026.29.4.001</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1587</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ПЕДИАТРИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>PEDIATRICS</subject></subj-group></article-categories><title-group><article-title>Холестатические заболевания печени у детей: опыт применения селективного ингибитора транспортера желчных кислот (IBAT)</article-title><trans-title-group xml:lang="en"><trans-title>Cholestatic liver diseases in children: experience with the use of a selective inhibitor of the bile acid transporter (IBAT)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0007-9018-8527</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кириллова</surname><given-names>М. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Kirillova</surname><given-names>Maria Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кириллова Мария Юрьевна, к.м.н., педиатр, ассистент кафедры детских болезней имени профессора И. М. Воронцова факультета послевузовского и дополнительного профессионального образования, гастроэнтеролог гастроэнтерологического отделения,</p><p>194100, Санкт-Петербург, ул. Литовская, 2. </p></bio><bio xml:lang="en"><p>Maria Yu. Kirillova, Cand. of Sci. (Med.), Pediatrician, Assistant of the Department of Pediatric Diseases named after Professor I. M. Vorontsov at the Faculty of Postgraduate and Additional Professional Education, Gastroenterologist of Gastroenterology Department,</p><p>2, Litovskaya str., St. Petersburg, 194100.</p></bio><email xlink:type="simple">tipikinamy@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2487-0783</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шилова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shilova</surname><given-names>Elena V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Шилова Елена Вадимовна, педиатр, гастроэнтеролог гастроэнтерологического отделения,</p><p>194100, Санкт-Петербург, ул. Литовская, 2. </p></bio><bio xml:lang="en"><p>Elena V. Shilova, Pediatrician, Gastroenterologist of Gastroenterology Department, </p><p>2, Litovskaya str., St. Petersburg, 194100.</p></bio><email xlink:type="simple">komarova_lena@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7931-2263</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Габрусская</surname><given-names>Т. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gabrusskaya</surname><given-names>Tatyana V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Габрусская Татьяна Викторовна, к.м.н., педиатр, доцент кафедры детских болезней имени И. М. Воронцова факультета послевузовского и дополнительного профессионального образования, гастроэнтеролог гастроэнтерологического отделения, </p><p>194100, Санкт-Петербург, ул. Литовская, 2. </p></bio><bio xml:lang="en"><p>Tatyana V. Gabrusskaya, Cand. of Sci. (Med.), Pediatrician, Associate Professor of the Department of Pediatric Diseases named after Professor I. M. Vorontsov at the Faculty of Postgraduate and Additional Professional Education, Gastroenterologist of Gastroenterology Department,</p><p>2, Litovskaya str., St. Petersburg, 194100.</p></bio><email xlink:type="simple">tatyanagabrusskaya@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-1262-4681</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Уланова</surname><given-names>Н. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Ulanova</surname><given-names>Natalya B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Уланова Наталья Борисовна, педиатр, гастроэнтеролог, заведующая гастроэнтерологическим отделением,</p><p>194100, Санкт-Петербург, ул. Литовская, 2. </p></bio><bio xml:lang="en"><p>Natalya B. Ulanova, Pediatrician, Gastroenterologist, Head of the Gastroenterology Department,</p><p>2, Litovskaya str., St. Petersburg, 194100.</p></bio><email xlink:type="simple">natulan@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0282-0953</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Волкова</surname><given-names>Н. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Volkova</surname><given-names>Natalya L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Волкова Наталья Леонидовна, педиатр, ассистент кафедры детских болезней имени профессора И. М. Воронцова факультета послевузовского и дополнительного профессионального образования, эндоскопист, гастроэнтеролог гастроэнтерологического отделения, </p><p>194100, Санкт-Петербург, ул. Литовская, 2. </p></bio><bio xml:lang="en"><p>Natalya L. Volkova, Pediatrician, Assistant of the Department of Pediatric Diseases named after Professor I. M. Vorontsov at the Faculty of Postgraduate and Additional Professional Education, Gastroenterologist, Endoscopist of Gastroenterology Department,</p><p>2, Litovskaya str., St. Petersburg, 194100.</p></bio><email xlink:type="simple">volkovanatalia.dr@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0001-3562-6412</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Килина</surname><given-names>С. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Kilina</surname><given-names>Sofia G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Килина Софья Геннадьевна, педиатр кафедры детских болезней имени профессора И. М. Воронцова факультета послевузовского и дополнительного профессионального образования, гастроэнтеролог гастроэнтерологического отделения,</p><p>194100, Санкт-Петербург, ул. Литовская, 2. </p></bio><bio xml:lang="en"><p>Sofia G. Kilina, Pediatrician of the Department of Pediatric Diseases named after Professor I. M. Vorontsov at the Faculty of Postgraduate and Additional Professional Education, Gastroenterologist of Gastroenterology Department,</p><p>2, Litovskaya str., St. Petersburg, 194100.</p></bio><email xlink:type="simple">sofiakilina-ivanova@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный педиатрический медицинский университет» Министерства здравоохранения Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Federal State Budgetary Educational Institution of Higher Education Saint Petersburg State Pediatric Medical University of the Ministry of Health of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>22</day><month>04</month><year>2026</year></pub-date><volume>0</volume><issue>4</issue><fpage>10</fpage><lpage>16</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Кириллова М.Ю., Шилова Е.В., Габрусская Т.В., Уланова Н.Б., Волкова Н.Л., Килина С.Г., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Кириллова М.Ю., Шилова Е.В., Габрусская Т.В., Уланова Н.Б., Волкова Н.Л., Килина С.Г.</copyright-holder><copyright-holder xml:lang="en">Kirillova M.Y., Shilova E.V., Gabrusskaya T.V., Ulanova N.B., Volkova N.L., Kilina S.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1587">https://journal.lvrach.ru/jour/article/view/1587</self-uri><abstract><sec><title>Введение</title><p>Введение. Холестатические заболевания печени являются актуальной проблемой современной гастроэнтерологии детского возраста, поскольку оказывают существенное влияние на качество жизни не только детей, но и семьи в целом, часто приводят к инвалидизации, высокой летальности, а также являются одним из основных показаний к трансплантации печени. В педиатрической практике различные заболевания печени могут проявляться холестазом, который представляет собой патологический процесс, характеризующийся нарушением синтеза или оттока желчи, что приводит к накоплению ее компонентов (желчных кислот, билирубина, холестерина) в организме и прогрессирующему повреждению печеночной ткани. Данное патологическое состояние может быть обусловлено анатомическими обструкциями, аномалиями развития структур билиарной системы, инфекциями различной этиологии, метаболическими заболеваниями или генетически детерминированными дефектами ферментных и транспортных систем, приводящими к нарушению процессов синтеза и экскреции желчных кислот, а также повреждению гепатоцитов и эпителиальных клеток желчных протоков.</p></sec><sec><title>Цель работы</title><p>Цель работы. Рассказать на клиническом примере об одной из редких генетических патологий – прогрессирующем семейном внутрипеченочном холестазе 3-го типа. Это аутосомно-рецессивное заболевание, обусловленное дефектами гена ABCB4, кодирующего транспортный белок MDR3, ответственный за секрецию фосфолипидов в желчь. Заболевание манифестирует в раннем детском возрасте и характеризуется прогрессирующим холестазом, интенсивным кожным зудом, задержкой физического развития и высоким риском формирования цирроза печени. Диагностика прогрессирующего семейного внутрипеченочного холестаза 3-го типа представляет значительные трудности ввиду отсутствия патогномоничных клинических признаков и требует применения молекулярно-генетических методов верификации.</p></sec><sec><title>Заключение</title><p>Заключение. В статье представлен клинический случай прогрессирующего семейного внутрипеченочного холестаза 3-го типа у девочки, диагностированного в возрасте 1 года 6 месяцев, с подтвержденной гомозиготной мутацией c.2534G&gt;T в гене ABCB4. Впервые в отечественной практике описан опыт применения одевиксибата, селективного ингибитора кишечного транспортера желчных кислот, у данной категории пациентов.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Cholestatic liver diseases represent a pressing issue in modern pediatric gastroenterology. They significantly impact the quality of life of both children and their families, often lead to disability and high mortality rates, and are a primary indication for liver transplantation. In pediatric practice, various liver diseases can manifest with cholestasis, a pathological process characterized by impaired bile synthesis or flow, leading to the accumulation of bile components (bile acids, bilirubin, cholesterol) in the body and progressive damage to liver tissue. This pathological condition can be caused by anatomical obstructions, developmental anomalies of the biliary tract structures, infections of various etiologies, metabolic diseases, or genetically determined defects in enzymatic and transport systems.</p></sec><sec><title>Objective</title><p>Objective. The purpose of this study is to provide a clinical example of a rare genetic disorder, progressive familial intrahepatic cholestasis type 3 (PFIC-3). These defects disrupt the processes of bile acid synthesis and excretion and cause damage to hepatocytes and epithelial cells of the bile ducts. One rare genetic pathology is Progressive Familial Intrahepatic Cholestasis type 3. This is an autosomal recessive disease caused by defects in the ABCB4 gene, which encodes the MDR3 transport protein responsible for phospholipid secretion into bile. The disease manifests in early childhood and is characterized by progressive cholestasis, intense pruritus, failure to thrive, and a high risk of developing liver cirrhosis. Diagnosing Progressive Familial Intrahepatic Cholestasis type 3 presents significant challenges due to the absence of pathognomonic clinical signs and requires the use of molecular genetic methods for verification.</p></sec><sec><title>Conclusion</title><p>Conclusion. The article presents a clinical case of Progressive Familial Intrahepatic Cholestasis type 3 in a girl, diagnosed at the age of 1 year and 6 months, with a confirmed homozygous mutation c.2534G&gt;T in the ABCB4 gene. For the first time in Russian practice, the experience of using odevixibat – a selective inhibitor of the intestinal bile acid transporter (IBAT) – in this category of patients is described. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>холестатические заболевания печени</kwd><kwd>прогрессирующий семейный внутрипеченочный холестаз 3-го типа</kwd><kwd>одевиксибат</kwd><kwd>ингибитор кишечного транспортера желчных кислот</kwd><kwd>холестатический зуд</kwd><kwd>желчные кислоты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cholestatic liver diseases</kwd><kwd>progressive familial intrahepatic cholestasis type 3</kwd><kwd>odevixibat</kwd><kwd>ileal bile acid transporter inhibitor</kwd><kwd>cholestatic pruritus</kwd><kwd>bile acids</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Gottesman L. E., Del Vecchio Mю T., Aronoff S. C. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatrics. 2015; 15: 192. DOI: 10.1186/s12887-015-0503-5.</mixed-citation><mixed-citation xml:lang="en">Gottesman L. E., Del Vecchio Mю T., Aronoff S. C. Etiologies of conjugated hyperbilirubinemia in infancy: a systematic review of 1692 subjects. BMC Pediatrics. 2015; 15: 192. DOI: 10.1186/s12887-015-0503-5.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Chen F., Huang Y., Huang Z., Fang F., Zhou H., Shu S. The epidemiological characteristics of liver disease in hospitalized children: a 10-year single-center retrospective study. Frontiers in Pediatrics. 2024; 12: 1344714. DOI: 10.3389/fped.2024.1344714.</mixed-citation><mixed-citation xml:lang="en">Chen F., Huang Y., Huang Z., Fang F., Zhou H., Shu S. The epidemiological characteristics of liver disease in hospitalized children: a 10-year single-center retrospective study. Frontiers in Pediatrics. 2024; 12: 1344714. DOI: 10.3389/fped.2024.1344714.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Fan Y.., Yu C., Lu C., Peng K., Zhao H., Chen C. Clinical and Genetic Features of Hereditary Liver Diseases in Children in China. Frontiers in Pediatrics. 2021; 9: 631620. DOI: 10.3389/fped.2021.631620.</mixed-citation><mixed-citation xml:lang="en">Fan Y.., Yu C., Lu C., Peng K., Zhao H., Chen C. Clinical and Genetic Features of Hereditary Liver Diseases in Children in China. Frontiers in Pediatrics. 2021; 9: 631620. DOI: 10.3389/fped.2021.631620.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Gonzalez H. K., Gordon S. K. Hepatic Manifestations of Systemic Diseases. Medical Clinics of North America. 2023; 107 (3): 465-489. DOI: 10.1016/j.mcna.2023.01.008.</mixed-citation><mixed-citation xml:lang="en">Gonzalez H. K., Gordon S. K. Hepatic Manifestations of Systemic Diseases. Medical Clinics of North America. 2023; 107 (3): 465-489. DOI: 10.1016/j.mcna.2023.01.008.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Sze Y. K., Dhawan A., Taylor R. M., Bansal S., Mieli-Vergani G., Rela M., et al. Liver Transplantation in Children with Metabolic Liver Diseases: The Royal College Hospital Experience. Transplantation. 2009; 87 (1): 87-93. DOI: 10.1097/TP.0b013e31818bc0c4.</mixed-citation><mixed-citation xml:lang="en">Sze Y. K., Dhawan A., Taylor R. M., Bansal S., Mieli-Vergani G., Rela M., et al. Liver Transplantation in Children with Metabolic Liver Diseases: The Royal College Hospital Experience. Transplantation. 2009; 87 (1): 87-93. DOI: 10.1097/TP.0b013e31818bc0c4.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet Journal of Rare Diseases. 2009; 4: 1. DOI: 10.1186/1750-1172-4-1.</mixed-citation><mixed-citation xml:lang="en">Davit-Spraul A., Gonzales E., Baussan C., Jacquemin E. Progressive familial intrahepatic cholestasis. Orphanet Journal of Rare Diseases. 2009; 4: 1. DOI: 10.1186/1750-1172-4-1.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Van Wessel D. B. E., Thompson R. J., Gonzales E., et al. Genotype correlates with disease severity in progressive familial intrahepatic cholestasis type 1 and 2. Hepatology. 2020; 73 (1): 84-98. DOI: 10.1002/hep.31095.</mixed-citation><mixed-citation xml:lang="en">Van Wessel D. B. E., Thompson R. J., Gonzales E., et al. Genotype correlates with disease severity in progressive familial intrahepatic cholestasis type 1 and 2. Hepatology. 2020; 73 (1): 84-98. DOI: 10.1002/hep.31095.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Van Wessel D. B. E., Koot B. G. P., Kamath B. M., et al. Native liver survival in progressive familial intrahepatic cholestasis: lessons from a large international cohort. Journal of Hepatology. 2020; 73 (1): 84-92. DOI: 10.1016/j.jhep.2020.01.019.</mixed-citation><mixed-citation xml:lang="en">Van Wessel D. B. E., Koot B. G. P., Kamath B. M., et al. Native liver survival in progressive familial intrahepatic cholestasis: lessons from a large international cohort. Journal of Hepatology. 2020; 73 (1): 84-92. DOI: 10.1016/j.jhep.2020.01.019.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Тихонов И. Н., Жаркова М. С., Маевская М. В., Павлов Ч. С., Некрасова Т. П., Шептулина А. Ф., Ивашкин В. Т. Рецидивирующий холестаз у пациента 16 лет. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (4): 103-115.</mixed-citation><mixed-citation xml:lang="en">Tikhonov I. N., Zharkova M. S., Maevskaya M. V., Pavlov Ch. S., Nekrasova T. P., Sheptulina A. F., Ivashkin V. T. Recurrent Cholestasis in a 16-Year-Old Patient. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii. 2016; 26 (4): 103-115. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Uchida H., Tiao G. M., Shivakumar P., Wong K. K. Y., Asai A, Amano H. Editorial: Infants with cholestasis. Frontiers in Pediatrics. 2023; 11: 1175231. DOI: 10.3389/fped.2023.1175231.</mixed-citation><mixed-citation xml:lang="en">Uchida H., Tiao G. M., Shivakumar P., Wong K. K. Y., Asai A, Amano H. Editorial: Infants with cholestasis. Frontiers in Pediatrics. 2023; 11: 1175231. DOI: 10.3389/fped.2023.1175231.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hassan S., Hertel P. Review of Progressive Familial Intrahepatic Cholestasis. Clinics and Research in Hepatology and Gastroenterology. 2022; 26: 371-390.</mixed-citation><mixed-citation xml:lang="en">Hassan S., Hertel P. Review of Progressive Familial Intrahepatic Cholestasis. Clinics and Research in Hepatology and Gastroenterology. 2022; 26: 371-390.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson R. J., Arnell H., Artan R., Baumann U., Calvo P. L., Chubkovski P., et al. Treatment with odevixibat for progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. The Lancet Gastroenterology &amp; Hepatology. 2022; 7 (9): 830-842. DOI: 10.1016/S2468-1253(22)00093-0.</mixed-citation><mixed-citation xml:lang="en">Thompson R. J., Arnell H., Artan R., Baumann U., Calvo P. L., Chubkovski P., et al. Treatment with odevixibat for progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial. The Lancet Gastroenterology &amp; Hepatology. 2022; 7 (9): 830-842. DOI: 10.1016/S2468-1253(22)00093-0.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Гудков Р. А., Дмитриев А. В., Федина Н. В., Петрова В. И. Прогрессирующий семейный внутрипеченочный холестаз у детей. Вестник Авиценны. 2025; 27 (1): 143-154. DOI: 10.25005/2074-0581-2025-27-1-143-154.</mixed-citation><mixed-citation xml:lang="en">Gudkov R. A., Dmitriev A. V., Fedina N. V., Petrova V. I. Progressive familial intrahepatic cholestasis in children. Vestnik Avitsenny. 2025; 27 (1): 143-154. DOI: 10.25005/2074-0581-2025-27-1-143-154. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. Journal of Hepatology. 2009; 51 (2): 237-267. DOI: 10.1016/j.jhep.2009.04.009.</mixed-citation><mixed-citation xml:lang="en">European Association for the Study of the Liver. EASL clinical practice guidelines: management of cholestatic liver diseases. Journal of Hepatology. 2009; 51 (2): 237-267. DOI: 10.1016/j.jhep.2009.04.009.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Tajiri K., Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World Journal of Gastroenterology. 2017; 23 (19): 3418-3426. DOI: 10.3748/wjg.v23.i19.3418.</mixed-citation><mixed-citation xml:lang="en">Tajiri K., Shimizu Y. Recent advances in the management of pruritus in chronic liver diseases. World Journal of Gastroenterology. 2017; 23 (19): 3418-3426. DOI: 10.3748/wjg.v23.i19.3418.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clinics and Research in Hepatology and Gastroenterology. 2012; 36 (Suppl 1): S3-S12. DOI: 10.1016/S2210-7401(12)70015-3.</mixed-citation><mixed-citation xml:lang="en">Poupon R. Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clinics and Research in Hepatology and Gastroenterology. 2012; 36 (Suppl 1): S3-S12. DOI: 10.1016/S2210-7401(12)70015-3.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Davit-Spraul A., Fabre M., Branchereau S., et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010; 51 (5): 1645-1655. DOI: 10.1002/hep.23539.</mixed-citation><mixed-citation xml:lang="en">Davit-Spraul A., Fabre M., Branchereau S., et al. ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history. Hepatology. 2010; 51 (5): 1645-1655. DOI: 10.1002/hep.23539.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Willot S., Uhlen S., Michaud L., Briand G., Bonnevalle M., Sfeir R., Gottrand F. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics. 2008; 122 (6): e1236-e1241. DOI: 10.1542/peds.2008-0986.</mixed-citation><mixed-citation xml:lang="en">Willot S., Uhlen S., Michaud L., Briand G., Bonnevalle M., Sfeir R., Gottrand F. Effect of ursodeoxycholic acid on liver function in children after successful surgery for biliary atresia. Pediatrics. 2008; 122 (6): e1236-e1241. DOI: 10.1542/peds.2008-0986.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Wietholtz H., Marschall H. U., Sjövall J., Matern S. Stimulation of bile acid 6-alpha-hydroxylation by rifampin. Journal of Hepatology. 1996; 24 (6): 713-718.</mixed-citation><mixed-citation xml:lang="en">Wietholtz H., Marschall H. U., Sjövall J., Matern S. Stimulation of bile acid 6-alpha-hydroxylation by rifampin. Journal of Hepatology. 1996; 24 (6): 713-718.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Does A. V., Levy C., Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. American Journal of Clinical Dermatology. 2022; 23: 647-659. DOI: 10.1007/s40257-022-00710-2.</mixed-citation><mixed-citation xml:lang="en">Does A. V., Levy C., Yosipovitch G. Cholestatic itch: our current understanding of pathophysiology and treatments. American Journal of Clinical Dermatology. 2022; 23: 647-659. DOI: 10.1007/s40257-022-00710-2.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Düll M. M., Kremer A. E. Newer approaches to the management of pruritus in cholestatic liver disease. Current Hepatology Reports. 2020; 19: 86-95. DOI: 10.1007/s11901-020-00517-x.</mixed-citation><mixed-citation xml:lang="en">Düll M. M., Kremer A. E. Newer approaches to the management of pruritus in cholestatic liver disease. Current Hepatology Reports. 2020; 19: 86-95. DOI: 10.1007/s11901-020-00517-x.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Kronsten V., Fitzpatrick E., Baker A. Management of cholestatic pruritus in paediatric patients with Alagille syndrome: the King's College Hospital experience. Journal of Pediatric Gastroenterology and Nutrition. 2013; 57 (2): 149-154. DOI: 10.1097/MPG.0b013e318297e384.</mixed-citation><mixed-citation xml:lang="en">Kronsten V., Fitzpatrick E., Baker A. Management of cholestatic pruritus in paediatric patients with Alagille syndrome: the King's College Hospital experience. Journal of Pediatric Gastroenterology and Nutrition. 2013; 57 (2): 149-154. DOI: 10.1097/MPG.0b013e318297e384.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Kuiper E. M., van Erpecum K. J., Beuers U., Hansen B. E., et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010; 52 (4): 1334-1340. DOI: 10.1002/hep.23821.</mixed-citation><mixed-citation xml:lang="en">Kuiper E. M., van Erpecum K. J., Beuers U., Hansen B. E., et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010; 52 (4): 1334-1340. DOI: 10.1002/hep.23821.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Bergasa N. V. The pruritus of cholestasis: from bile acids to opiate agonists: relevant after all these years. Medical Hypotheses. 2018; 110: 86-89. DOI: 10.1016/j.mehy.2017.11.002.</mixed-citation><mixed-citation xml:lang="en">Bergasa N. V. The pruritus of cholestasis: from bile acids to opiate agonists: relevant after all these years. Medical Hypotheses. 2018; 110: 86-89. DOI: 10.1016/j.mehy.2017.11.002.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Patel S. P., Vasavda K., Ho B., Meisoon J., Dong S., Kwatra S. G. Cholestatic pruritus: New mechanisms and treatment. Journal of the American Academy of Dermatology. 2019; 81: 1371-1378. DOI: 10.1016/j.jaad.2019.04.035.</mixed-citation><mixed-citation xml:lang="en">Patel S. P., Vasavda K., Ho B., Meisoon J., Dong S., Kwatra S. G. Cholestatic pruritus: New mechanisms and treatment. Journal of the American Academy of Dermatology. 2019; 81: 1371-1378. DOI: 10.1016/j.jaad.2019.04.035.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Browning J., Combes B., Mayo M. J. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. American Journal of Gastroenterology. 2003; 98 (12): 2736-2741. DOI: 10.1111/j.1572-0241.2003.08662.x.</mixed-citation><mixed-citation xml:lang="en">Browning J., Combes B., Mayo M. J. Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis. American Journal of Gastroenterology. 2003; 98 (12): 2736-2741. DOI: 10.1111/j.1572-0241.2003.08662.x.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kamath B. M., Stein P., Howen R. H., Verkade H. J. The potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver International. 2020; 40: 1812-1822. DOI: 10.1111/liv.14553.</mixed-citation><mixed-citation xml:lang="en">Kamath B. M., Stein P., Howen R. H., Verkade H. J. The potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis. Liver International. 2020; 40: 1812-1822. DOI: 10.1111/liv.14553.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Van der Wurth V. L., Howen R. H., van de Graaf S. F. Current and Future Therapies for Hereditary Cholestatic Liver Diseases. World Journal of Gastroenterology. 2017; 23: 763-775. DOI: 10.3748/wjg.v23.i5.763.</mixed-citation><mixed-citation xml:lang="en">Van der Wurth V. L., Howen R. H., van de Graaf S. F. Current and Future Therapies for Hereditary Cholestatic Liver Diseases. World Journal of Gastroenterology. 2017; 23: 763-775. DOI: 10.3748/wjg.v23.i5.763.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Verkade H. J., Loomes K. M., Stoll J. M., Gu T., Loizides A., Maucksch C. Efficacy and safety of odevixibat in a subgroup of adult patients with progressive familial intrahepatic cholestasis in the PEDFIC 2 study. Journal of Hepatology. 2024; 80: S715-S716.</mixed-citation><mixed-citation xml:lang="en">Verkade H. J., Loomes K. M., Stoll J. M., Gu T., Loizides A., Maucksch C. Efficacy and safety of odevixibat in a subgroup of adult patients with progressive familial intrahepatic cholestasis in the PEDFIC 2 study. Journal of Hepatology. 2024; 80: S715-S716.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Dicks E. Odevixibat: first approval. Drugs. 2021; 81 (15): 1781-1786. DOI: 10.1007/s40265-021-01594-y. Erratum in: Drugs. 2021; 81 (15): 1815. DOI: 10.1007/s40265-021-01608-9.</mixed-citation><mixed-citation xml:lang="en">Dicks E. Odevixibat: first approval. Drugs. 2021; 81 (15): 1781-1786. DOI: 10.1007/s40265-021-01594-y. Erratum in: Drugs. 2021; 81 (15): 1815. DOI: 10.1007/s40265-021-01608-9.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson R. J., Arnel L H., Artan R., et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomized, placebo-controlled, phase 3 trial. The Lancet Gastroenterology &amp; Hepatology. 2022; 7 (9): 830-842. DOI: 10.1016/S2468-1253(22)00093-0.</mixed-citation><mixed-citation xml:lang="en">Thompson R. J., Arnel L H., Artan R., et al. Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomized, placebo-controlled, phase 3 trial. The Lancet Gastroenterology &amp; Hepatology. 2022; 7 (9): 830-842. DOI: 10.1016/S2468-1253(22)00093-0.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson R. J., Arnell H., Artan R., et al. Odevixibat in progressive familial intrahepatic cholestasis: efficacy and safety in the PEDFIC 2 trial [abstract]. In: The Liver Meeting 2022, American Association for the Study of Liver Diseases; 2022 Nov 4-8; Washington, DC. Alexandria: AASLD; 2022. p. A5.</mixed-citation><mixed-citation xml:lang="en">Thompson R. J., Arnell H., Artan R., et al. Odevixibat in progressive familial intrahepatic cholestasis: efficacy and safety in the PEDFIC 2 trial [abstract]. In: The Liver Meeting 2022, American Association for the Study of Liver Diseases; 2022 Nov 4-8; Washington, DC. Alexandria: AASLD; 2022. p. A5.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Thompson R. J., Durmaz Ö., Grammatikopoulos T., Di Giorgio A., Ni Q., Stein P., et al. Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results of ≥ 96 weeks of treatment [abstract]. Frontline Gastroenterology. 2023; 14 (Suppl 1): A6-A7.</mixed-citation><mixed-citation xml:lang="en">Thompson R. J., Durmaz Ö., Grammatikopoulos T., Di Giorgio A., Ni Q., Stein P., et al. Long-term efficacy and safety of odevixibat in patients with progressive familial intrahepatic cholestasis: results of ≥ 96 weeks of treatment [abstract]. Frontline Gastroenterology. 2023; 14 (Suppl 1): A6-A7.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Di Giorgio A., Schiveres M., Fuoti M., Calvo P., Cananzì M., Lleo A., et al. Real-life experience of using odevixibat in children with progressive familial intrahepatic cholestasis. JHEP Reports. 2024; 7 (4): 101309. DOI: 10.1016/j.jhepr.2024.101309.</mixed-citation><mixed-citation xml:lang="en">Di Giorgio A., Schiveres M., Fuoti M., Calvo P., Cananzì M., Lleo A., et al. Real-life experience of using odevixibat in children with progressive familial intrahepatic cholestasis. JHEP Reports. 2024; 7 (4): 101309. DOI: 10.1016/j.jhepr.2024.101309.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
